PKR

Data indicated a trend toward reduced incidence of vaso-occlusive crises over 52 weeks and increased hemoglobin response at 24 weeks compared with placebo Results to be confirmed in the phase 3 component of the HIBISCUS trial PLAINSBORO, N.J., Dec. 7, 2024 /PRNewswire/ -- Novo Nordisk today announced 52-week results from the phase 2 part of the ongoing phase 2/3 HIBISCUS study program of investigational etavopivat in people with sickle cell disease. These results were presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) in San Diego, California. Results from this part of the study have been used to determine the dose for the ongoing phase 3 HIBISCUS study program. Based on the totality of data, proof of concept of etavopivat was established in sickle cell disease, indicating a trend towards reduced incidence of vaso-occlusive crises (VOCs — severe pain caused when blood vessels are blocked and deprive tissues of oxygen) over 52 weeks and increased hemoglobin response at week 24 compared with placebo.1,2 The results will attempt to be confirmed in the phase 3 component of the HIBISCUS trial. "Due to decades of underfunding and the lack of a long-term, ongoing clinical registry, there have been few treatments approved for people living with sickle cell disease. As a result, affected individuals often face a lifetime of debilitating pain and reduced quality of life," said Dr. Julie Kanter, co-director of the Lifespan Comprehensive Sickle Cell Center and professor in the Division of Hematology and Oncology at the University of Alabama at Birmingham. "Acute pain crises are a recognized hallmark of sickle cell disease, resulting in significant pain that can lead to organ damage as well as emergency department visits and hospitalizations. We need more treatment options for people with sickle cell disease to help address the unmet need in this community. Etavopivat is a promising investigational treatment for patients with sickle cell disease and I look forward to seeing how this may impact the treatment landscape." At week 52 in the intent-to-treat population (n=60), annualized VOC rates were 1.07 and 1.06 for the etavopivat 200 mg and 400 mg groups, respectively, and 1.97 for the placebo group.2 The median time to first VOC was 33.6 weeks for both etavopivat groups compared with 16.9 weeks for placebo.2 At week 24, hemoglobin response (>1 g/dL increase from baseline) was higher in the etavopivat groups with 38% and 25% responding in the 200 mg and 400 mg groups, respectively, compared with 10.5% in the placebo group.2 Patient-reported outcome measures using the PROMIS Fatigue Scale showed numerical improvements for participants receiving etavopivat compared with those receiving placebo.2 In the per-protocol population (defined as 80% or higher protocol compliance and completion of the double-blind period with no major protocol deviations), annualized VOC rates were 0.66 (n=13) and 0.7 (n=12) for the etavopivat 200 mg and 400 mg groups, respectively, and 1.77 (n=15) for the placebo group.2 Hemoglobin response at week 24 was 46% (n=6/13) and 33% (n=4/12) in the 200 mg and 400 mg groups, and 13% (n=2/15) in the placebo group.2 Two SAEs were identified to be possibly/probably drug-related, hepatic enzyme increase in one patient in the etavopivat 200 mg group and hemoglobin decrease in one patient in the etavopivat 400 mg group.2 Two SAEs leading to permanent discontinuation were reported in the etavopivat 200 mg group, hepatic enzyme increase and a cerebrovascular accident.2 "At Novo Nordisk, we have a 35+ year legacy and expertise in hematology and rare disease, and our ambition is to transform the standard of care for people with sickle cell disease by developing treatments that not only alleviate symptoms but also modify the course of the disease," said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk.3 "Although additional studies are needed, emerging results from HIBISCUS may mark a significant step forward in achieving this ambition and potentially providing people living with sickle cell disease with an option that can help manage symptoms and disease progression." About sickle cell disease Sickle cell disease is a debilitating, life-threatening group of rare, inherited red blood cell disorders caused by a mutation in the hemoglobin gene.4 This mutation causes red blood cells to become stiff and half-moon or 'sickle' shaped.4 Sickle cells are less effective at carrying oxygen, do not last as long as healthy cells, and risk getting stuck in blood vessels, leading to blockages known as vaso-occlusion.1,5-8 Sickle cell disease is characterized by acute and chronic pain, anemia, and fatigue alongside VOCs, which can require hospitalization and can lead to complications, including organ damage.4,7,8 Globally, there are almost 8 million people living with sickle cell disease.9 About HIBISCUS HIBISCUS (NCT04624659) is a multi-center, phase 2/3, randomized, double-blind, placebo-controlled study program investigating the safety profile and efficacy of etavopivat in sickle cell disease.10 The phase 2 dose-determination cohort enrolled 60 patients with sickle cell disease, randomized 1:1:1 to receive etavopivat 200 mg, 400 mg, or placebo over 52 weeks.10 The phase 3 efficacy part of HIBISCUS will randomize approximately 380 patients with sickle cell disease 1:1 to receive the selected dose of etavopivat (400 mg) or placebo.10 Participants in HIBISCUS can continue for an additional 52 weeks of treatment in an open-label extension phase and have the option to participate in a long-term roll-over study.10 The primary endpoints of HIBISCUS are annualized VOC rate at week 52 and hemoglobin response rate at week 24, measured as an increase of >1 g/dL from baseline.10 Key secondary endpoints are time-to-first VOC, change in hemolysis biomarkers (absolute reticulocyte count, indirect bilirubin, and lactate dehydrogenase), and a patient-reported outcome measure (PROMIS Fatigue Scale).10 About etavopivat Etavopivat is an investigational, oral, small-molecule activator of erythrocyte pyruvate kinase (PKR) in development for the treatment of sickle cell disease and other hemoglobinopathies.11 Etavopivat-mediated activation of PKR lowers levels of 2,3- diphosphoglycerate (2,3-DPG) and raises adenosine triphosphate (ATP) levels in red blood cells, which has the potential to increase oxygen affinity, reduce hemolysis, and decrease VOCs.11-13 About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn, and YouTube. Contacts for further information References Jang T, Poplawska M, Cimpeanu E, et al. Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events. J. Transl. Med. 2021;19(1):397. Delicou S, El Rassi F, et al. Etavopivat reduces incidence of vaso-occlusive crises in patients with sickle cell disease: HIBISCUS trial phase 2 results through 52 weeks. 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) 7-10 December 2024, San Diego, US. 179. Novo Nordisk. Data on File. American Society of Hematology. Sickle Cell Disease. Accessed December 2024. Available at . Safo MK, Kato GJ. Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin. Hematol Oncol Clin North Am. 2014;28(2):217–231. National Heart, Lung, and Blood Institute. What Is Sickle Cell Disease? Accessed December 2024. Available at . Bailey M, Abioye A, Morgan G, et al. Relationship between Vaso-Occlusive Crises and Important Complications in Sickle Cell Disease Patients. Blood. 2019; 134 (Supplement_1):2167. National Organization for Rare Disorders (NORD). Sickle cell disease. Rare Diseases. Accessed December 2024. Available at . Thomson AM, et al. GBD 2021 Sickle Cell Disease Collaborators. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol. 2023;10(8):e585–e599. Clinicaltrials.gov. A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS). Accessed December 2024. Available at . Saraf SL, Hagar R, Idowu M, et al. Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease. Blood Adv. 2024;8(16):4459–4475. Barros GDS, Leal CVF, Leite LAC, Fujimoto DE, Cançado RD. Real-world evidence of the burden of sickle cell disease: a 5-year longitudinal study at a Brazilian reference center. Hematol Transfus Cell Ther. 2024;46(2):161-166. doi:10.1016/j.htct.2023.10.001 Schroeder, P et al. Etavopivat for the treatment of sickle cell disease. J Pharmacol Exp. 2022; 380(3):210-219. Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2024 Novo Nordisk All rights reserved. US24SCD00030 December 2024 SOURCE Novo Nordisk WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Bagsværd, Denmark, 3 December 2024 – Novo Nordisk today announced the presentation of 13 abstracts, three of which will be presented in oral sessions, at the upcoming 66 th Annual Meeting and Exposition of the American Society of Hematology (ASH), which will take place from 7 to 10 December 2024 in San Diego, California. In an oral presentation on 7 December, 52-week results from the phase 2 part of the ongoing phase 2/3 HIBISCUS trial of etavopivat will be presented. These results have determined the dose for the phase 3 part of the trial, as well as examined the safety profile and efficacy of etavopivat, including the incidence of vaso-occlusive crises (severe pain caused when blood vessels are blocked and deprive tissues of oxygen 1 ) in patients with sickle cell disease. The results from HIBISCUS have been chosen to be highlighted in the ASH Annual Meeting Press Program session ‘Reading Up on the Classics: Treating Not-So-Benign Hematology Conditions’ on 7 December at 08.30 PST. From Novo Nordisk’s haemophilia portfolio, there are two oral presentations of note: first on the efficacy and safety results of an interim analysis from FRONTIER4, a phase 3 open-label, multi-centre extension study of Mim8 in people living with haemophilia A with and without inhibitors (HA/HAwI). Additionally, an oral presentation of data from the phase 3 explorer7 study assessing the efficacy of concizumab in people with haemophilia A or B with inhibitors (HAwI/HBwI), with or without recurring bleeds into the same joint (or target joints) at baseline. “There is a significant unmet need for novel treatment options that have the potential to transform care for people with rare blood disorders globally," said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk. “I am particularly excited that we at the ASH congress will present new data from our pipeline in sickle cell disease, a first for Novo Nordisk. Sickle cell disease affects approximately eight million people worldwide with big consequences for the individual patient, yet there are few treatment options available. Our sickle cell research builds on our legacy in haemophilia, where we continue to advance research to address the unmet needs of patients.” Summary of presentations Accepted data at the 66 th ASH annual meeting include the following poster and oral presentations. Accepted abstracts include preliminary data that may be subject to change in final manuscripts, which will be published in the journal Blood following the congress. Dates and times of the presentations can be found on the ASH website . Sickle cell disease Haemophilia About sickle cell disease Sickle cell disease is a debilitating, life-threatening group of rare, inherited red blood cell disorders caused by a mutation in the haemoglobin gene within red blood cells 2,3 . This mutation causes red blood cells to become stiff and half-moon or ‘sickle’ shaped 2 . Sickle cells are less effective at carrying oxygen, do not last as long as healthy cells and risk getting stuck in blood vessels, leading to blockages known as vaso-occlusion 1,4 – 7 . Sickle cell disease is characterised by acute and chronic pain, anaemia and fatigue alongside vaso-occlusive crises (VOCs), which can require hospitalisation and can lead to complications, including organ damage 8 . Globally, almost 8 million people are living with sickle cell disease 9 . About etavopivat Etavopivat is an investigational, oral, small-molecule activator of erythrocyte pyruvate kinase (PKR) activator in development for the treatment of sickle cell disease and other haemoglobinopathies 10 . Etavopivat-mediated activation of PKR lowers levels of 2,3- diphosphoglycerate (2,3-DPG) and raises adenosine triphosphate (ATP) levels, which has the potential to improve oxygen bind to haemoglobin (i.e. increase oxygen affinity), reduce haemolysis and decrease VOCs by improving red blood cell health 10 . About haemophilia Haemophilia is a rare inherited bleeding disorder that impairs the body’s ability to make blood clots, a process needed to stop bleeding. It is estimated to affect approximately 1,125,000 people worldwide 11 . Due to the nature of haemophilia being an x-linked recessive disorder, it often presents differently in males compared to females, with ~ 88% of people diagnosed with haemophilia worldwide being male 12,13 . There are different types of haemophilia, which are characterised by the type of clotting factor protein that is defective or missing. Haemophilia A is caused by a missing or defective clotting Factor VIII (FVIII), and haemophilia B is caused by a missing or defective clotting Factor IX (FIX). About Mim8 Mim8 is an investigational Factor VIIIa (FVIIIa) mimetic bispecific antibody designed with the potential to deliver sustained haemostasis for once-monthly, once every two weeks or once-weekly prophylaxis for people living with haemophilia A with and without inhibitors. Administered under the skin, Mim8 bridges Factor IXa and Factor X. This action replaces Factor VIII, which restores the body’s thrombin generation capacity, helping blood to clot. The use of Mim8 in people living with haemophilia A is investigational and not approved by regulatory authorities anywhere in the world. About Alhemo ® (concizumab) Alhemo ® (concizumab) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody designed to block a protein in the body that stops blood from clotting, called TFPI. By blocking TFPI, Alhemo ® encourages the production of thrombin, which helps to clot the blood and prevent bleeding 14 . Alhemo ® is currently approved in Australia 15 and Switzerland 16 for the treatment of adolescents and adults (12 years or older) with haemophilia A or B with inhibitors; in Japan, Alhemo ® is currently approved for the treatment of adolescents and adults (12 years or older) with haemophilia A or B with and without inhibitors 17 . In all approved countries, it is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes. Alhemo ® received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) on 17 October 2024 18 . About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information

Clinical data include analyses of novel, investigational therapies with the potential to help address unmet needs in sickle cell disease and hemophilia New data from the HIBISCUS phase 2 trial evaluating the efficacy and safety of etavopivat will be featured in ASH press briefing Key findings from one phase 3 trial evaluating the efficacy and safety of Mim8 prophylaxis and two phase 3 trials evaluating the impact of concizumab on hemophilia A and B with inhibitors supports Novo Nordisk's ongoing commitment to rare blood disorders PLAINSBORO, N.J., Dec. 3, 2024 /PRNewswire/ -- Novo Nordisk today announced the presentation of 13 abstracts at the upcoming 66th Annual Meeting and Exposition of the American Society of Hematology (ASH), which will take place from 7 to 10 December 2024 in San Diego, California. New results from the phase 2/3 HIBISCUS trial of investigational etavopivat in patients with sickle cell disease will be presented to determine the dose for the phase 3 part of the trial, as well as examine the safety and efficacy of etavopivat. This includes the incidence of vaso-occlusive crises, which occur when sickled red blood cells block blood flow, causing extreme pain. The HIBISCUS data will be highlighted in the ASH Annual Meeting Press Program session: Reading Up on the Classics: Treating Not-So-Benign Hematology Conditions on 7 December at 08:30 PST. There are two oral presentations of note from Novo Nordisk's investigational hemophilia portfolio. The first explores the efficacy and safety results of an interim analysis from FRONTIER4, a phase 3 open-label, multi-center extension study of Mim8 in people living with hemophilia A with and without inhibitors (HA/HAwI). Additionally, new data from the phase 3 explorer7 study assesses the efficacy of concizumab in people with hemophilia A or B with inhibitors (HAwI/HBwI), with or without recurring bleeds into the same joint (or target joints) at baseline. "There is a significant unmet need for novel treatment options that have the potential to transform care for people with rare blood disorders globally," said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk. "I am particularly excited that we at the ASH congress will present new data from our pipeline in sickle cell disease, a first for Novo Nordisk. Sickle cell disease affects approximately eight million people worldwide with big consequences for the individual patient, yet there are few treatment options available. Our sickle cell research builds on our legacy in hemophilia, where we continue to advance research to address the unmet needs of patients." Summary of presentations Accepted data at the 66th ASH annual meeting includes the following poster and oral presentations. Accepted abstracts include preliminary data that may be subject to change in final manuscripts which will be published in the journal Blood following the congress. Dates and times of the presentations can be found on the ASH website. Sickle cell disease Investigational etavopivat Etavopivat reduces incidence of vaso-occlusive crises in patients with sickle cell disease: HIBISCUS trial phase 2 results through 52 weeks (179-O) Etavopivat increases arterial hemoglobin-oxygen saturation during moderate and severe hypoxia: a mechanistic phase 1 trial in healthy volunteers (2461-P) General sickle cell disease Large scale analysis of the real-world association between fetal hemoglobin and vaso-occlusive crises in sickle cell disease (1124-P) Characterizing people with sickle cell disease who share attitudes regarding clinical trial participation: findings from the global LISTEN survey (1135-P) How people with sickle cell disease rate motivators is associated with the likelihood of wanting to participate in a clinical trial: findings from the global LISTEN survey (1137-P) Motivators and barriers for people with sickle cell disease participating in clinical trials: United States findings from the LISTEN survey (1139-P) Noninvasive, accessible, smartphone app for at home hemoglobin monitoring in sickle cell disease (2248-P) Hemophilia Investigational Mim8 Safety and efficacy of Mim8 prophylaxis administered once every two weeks for patients with hemophilia A with or without inhibitors: interim analysis of the FRONTIER4 open-label extension study (718-O) Mim8 prophylaxis beyond bleeding: investigating multifaceted, patient-reported outcomes for hemophilia A in the FRONTIER2 study (1212-P) Investigational concizumab Annualized bleeding rates in patients with hemophilia A or B and inhibitors with and without target joints at baseline: results from the concizumab phase 3 explorer7 study (715-O) Unmet needs of patients with hemophilia A/B with or without inhibitors: real-world end-of-study results from the explorer6 non-interventional study (2585-P) General hemophilia Burden of treatment on people with hemophilia: global real-world data (5077-P) Physical and psychological burden on people with hemophilia: global real-world data (2318-P) About sickle cell disease Sickle cell disease (SCD) is a debilitating, life-threatening group of rare, inherited red blood cell disorders, caused by a mutation in the hemoglobin gene.1 This mutation causes red blood cells to become stiff and half-moon or 'sickle' shaped.1 Sickle cells are less effective at carrying oxygen, don't last as long as healthy cells and risk getting stuck in blood vessels, leading to blockages known as vaso-occlusion.2,3-7 Sickle cell disease is characterized by acute and chronic pain, anemia and fatigue alongside vaso-occlusive crises (VOCs), which can require hospitalization and can lead to complications including organ damage.4,7 Globally, there are almost 8 million people living with sickle cell disease.8 About etavopivat Etavopivat is an investigational, oral, small-molecule activator of erythrocyte pyruvate kinase (PKR) in development for the treatment of sickle cell disease and other hemoglobinopathies.9 Etavopivat-mediated activation of PKR lowers levels of 2,3 diphosphoglycerate (2,3 DPG) and raises adenosine triphosphate (ATP) levels, which has the potential to increase oxygen affinity, reduce hemolysis and decrease vaso-occlusive crises (VOCs).9,10 About hemophilia Hemophilia is a rare inherited bleeding disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding.11 It is estimated to affect approximately 1,125,000 people worldwide.12 There are different types of hemophilia, which are characterized by the type of clotting factor protein that is defective or missing.11 Hemophilia A is caused by a missing or defective clotting Factor VIII (FVIII), and hemophilia B is caused by a missing or defective clotting Factor IX (FIX).11 Hemophilia is often treated by replacing the missing clotting factor via intravenous infusions, also known as replacement therapy.13 However, sometimes the body can produce inhibitors as an immune response to the clotting factors in the therapy, which means replacement therapy does not work and limits overall treatment options.14 About Mim8 Mim8 is a FVIIIa mimetic bispecific antibody being investigated for once-weekly, once biweekly, and once-monthly prophylaxis for people living with hemophilia A, with and without inhibitors.15 Administered subcutaneously, Mim8 is designed to bridge Factor IXa/X (FIXa/FX) together upon activation, thereby replacing missing FVIII, which helps to restore thrombin generation capacity, and blood clotting.15,16 The use of Mim8 in people living with HA/HAwI is investigational and not approved by any regulatory authority. About concizumab Concizumab is an investigational tissue factor pathway inhibitor (TFPI) antagonist designed to block a protein in the body that stops blood from clotting.17 By blocking TFPI, concizumab encourages the production of thrombin, which helps to clot the blood and prevent bleeding.17 About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn, and YouTube. Contacts for further information References American Society of Hematology. Sickle Cell Disease. Accessed November 2024. Available at: . VCU Health. About sickle cell disease. Accessed November 2024. Available at . Safo MK, Kato GJ. Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin. Hematol Oncol Clin North Am. 2014;28(2):217–231. Jang T, Poplawska M, Cimpeanu E, et al. Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events. J Transl Med. 2021;19(1):397. National Heart, Lung, and Blood Institute. What Is Sickle Cell Disease? Accessed November 2024. Available at . Bailey M, Abioye A, Morgan G, et al. Relationship between vaso-occlusive crises and important complications in sickle cell disease patients. Blood. 2019; 134 (Supplement_1): 2167. National Organization for Rare Disorders (NORD). Sickle cell disease. Rare Diseases. Accessed November 2024. Available at . Thomson, AM, et al. GBD 2021 Sickle Cell Disease Collaborators. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol. 2023;10(8):e585–e599. Saraf SL, Hagar R, Idowu M, et al. Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease. Blood Adv. 2024;8(16):4459-4475. doi:10.1182/bloodadvances.2023012467. Schroeder, P et al. Etavopivat for the treatment of sickle cell disease. J Pharmacol Exp. 2022; 380(3):210-219. MedlinePlus. Hemophilia. Accessed: November 2024. Available at: . Iorio A, Stonebraker JS, Chambost H, et al; Data and demographics committee of the World Federation of Hemophilia. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171(8):540–546. Centers for Disease Control and Prevention (CDC). Treatment of Hemophilia. Accessed: November 2024. Available at: . Kim JY, You CW. The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A. Blood Res. 2019 Sep;54(3):204-209. doi: 10.5045/br.2019.54.3.204. Østergaard H, Lund J, Greisen PJ, et al. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021;138(14):1258-1268. doi:10.1182/blood.2020010331 U.S. National Library of Medicine. F8 gene. MedlinePlus Genetics. Accessed November 2024. Available at Matsushita T, Shapiro A, Abraham A, et al. Phase 3 Trial of concizumab in hemophilia with inhibitors. N Engl J Med. 2023;389:783–794. Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2024 Novo Nordisk All rights reserved. US24NNG00067 December 2024 SOURCE Novo Nordisk WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED